Case Report

All-Trans Retinoic Acid-Induced Pseudotumor Cerebri during Induction Therapy for Acute Promyelocytic Leukemia: A Case Report and Literature Review

Table 3

Common drug interactions with tretinoin [39].

Drug(s)Interaction

Antifibrinolytic agents (e.g., aminocaproic acid, aprotinin, and tranexamic acid)May increase risk of thrombosis during tretinoin therapy.
Drugs that induce cytochrome P-450 system (e.g., barbiturates, carbamazepine, phenytoin, primidone, rifabutin, and rifampin)May decrease tretinoin concentrations and antineoplastic efficacy.
Drugs that inhibit cytochrome P-450 (e.g., cimetidine, erythromycin, fluconazole, and ketoconazole)May increase tretinoin concentrations and toxicity. Adjust tretinoin concentrations when necessary.
Drugs that inhibit CYP-2C8 (e.g., atazanavir, gemfibrozil, and ritonavir)May increase tretinoin concentrations and toxicity. Adjust tretinoin concentrations when necessary.
Estrogen-progestin oral contraceptivesTretinoin may decrease contraceptive efficacy. The use of at least 1 other effective form of contraception during tretinoin therapy is recommended.
Progestin-only oral contraceptivesTretinoin may decrease contraceptive efficacy. The use of at least 2 other effective forms of contraception during tretinoin therapy is recommended.
Tetracycline antibiotics (e.g., doxycycline, minocycline, and tetracycline)May increase risk of PC.
EthanolMay increase CNS depression. Avoid concomitant use.
HydroxyureaSynergistic antineoplastic effects; may increase risk of cell lysis and potentially fatal bone marrow necrosis.
St. John’s wortMay decrease tretinoin concentrations and antineoplastic efficacy. Avoid concomitant use.
Vitamin AIncreased risk of vitamin A toxicity. Avoid combination.